Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CytomX Therapeutics, Inc. (CTMX)

CytomX Q3 revenue falls to $1.7 million; net loss widens to $20.0 million

Negative Impact 3 of 5 earnings Written later

CytomX reported unaudited third-quarter 2026 results with revenue of $1.7 million, down from $6.0 million a year earlier, as the Astellas collaboration performance obligation concluded in the second quarter of 2026. The net loss widened to $20.0 million from $14.2 million, while operating expenses rose to $25.2 million, and the company ended the quarter with $348.0 million in cash, cash equivalents and investments, with cash runway expected into the second half of 2028.

Key points

  • Q3 2026 revenue was $1.7 million versus $6.0 million in Q3 2025; nine-month revenue was $13.4 million versus $75.5 million.
  • Q3 2026 net loss was $20.0 million, or $0.09 per share, versus a net loss of $14.2 million, or $0.09 per share, a year earlier.
  • Operating expenses rose to $25.2 million from $21.7 million, led by research and development at $16.5 million and general and administrative at $8.7 million.
  • Varseta-M received FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer in August 2026; a Phase 1 monotherapy data update is expected in January 2027.

The filing

CompanyCytomX Therapeutics, Inc. (CTMX)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:07 PM ET
Accession number0001193125-26-449787

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.